Skip to content
PRISM BioLab
  • PRISM BioLab Blog – PPI Pursuit
  • News & Publications
    • News
    • Publications
  • Careers
  • Contact Us
  • About Us
    • Management Team
    • Team Members
    • Scientific Advisory Board
  • Technology
    • Peptide Mimetics
    • “PepMetics”® Library
    • Sequence Mimetics: Cyclic & Stapled Peptides
    • Structure-Based Drug Design
    • Targeting Intrinsically Disordered Proteins
    • Patents
  • Pipeline
  • “PepMetics”® Library
  • Partners & Collaborators
Menu
en_US English
en_US English ja Japanese

News

PRISM BioLab > News & Publications > News
  •          
  • Print
  • News & Publications
  • News
  • Publications
  • News & Publications
  • News
  • Publications
PRISM BioLab > News & Publications > News
May 27, 2024

Notice of Approval for Listing on the Growth Market of the Tokyo Stock Exchange

PRISM BioLab is pleased to announce that the Tokyo Stock Exchange today approved the initial listing...
Read More
April 25, 2024

PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono

TOKYO, Japan, 25 Apr 2024: -- PRISM BioLab, Co. Ltd. , a leading discovery and development...
Read More
April 21, 2024

Announcement of setting the record date for stock split

Announcement of setting the record date for stock split(pdf)
Read More
January 24, 2024

PRISM BioLab raises 1.5 billion yen in Series C fundraising to advance technologies and programs targeting protein-protein interactions

TOKYO, Japan, 24 Jan 2024: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology...
Read More
November 29, 2023

PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target

TOKYO, Japan, 28 Nov 2023: –PRISM BioLab, Co. Ltd. , a leading discovery and development biotechnology...
Read More
May 31, 2023

PRISM BioLab announces a milestone achievement based on the license agreement with Ohara Pharmaceutical

TOKYO, Japan, 31 May 2023: – PRISM BioLab, a Japan based biotechnology company with a proprietary...
Read More
January 13, 2023

New study by PRISM Biolab demonstrates rational design of small molecule inhibitors of CTLA-4 and B7-1 protein-protein interaction utilizing only a sequence of a binding peptide

The paper published in the special issue of Pharmaceuticals journal dedicated to “Small Molecules Targeting Protein-Protein...
Read More
October 31, 2022

Pharma Intelligence Award Japan 2022 Commemorative Webinar “PPI Inhibition by Small Molecules: A New Drug Discovery Paradigm”

PRISM BioLab's proprietary drug discovery platform, PepMetics®, is a technology that enables the control of protein-protein...
Read More
September 1, 2022

PRISM Biolab Wins Biotech Company of the Year Award of Informa Pharma Intelligence Award 2022

We are pleased to announce that we have won the Biotech company of the year in...
Read More
January 4, 2022

PRISM BioLab, enters multi-project drug discovery collaboration with Roche and Genentech

TOKYO, Japan, 5th Jan. 2022: -- PRISM BioLab, a Japan based biotechnology company with a proprietary...
Read More
« Previous 1 2 3 4 5 Next »

    PRISM is open to all levels of scientific discussion. Our scientists would love to speak with you!

    • Technology
    • Peptide Mimetics
    • “PepMetics”® Library
    • Sequence Mimetics: Cyclic & Stapled Peptides
    • Structure-Based Drug Design
    • Targeting Intrinsically Disordered Proteins
    • Patents
    • About Us
    • Management Team
    • Team Members
    • Scientific Advisory Board
    • News & Publications
    • News
    • Publications
    • Quick Links
    • About Us
    • Pipeline
    • Partners & Collaborators
    • Careers
    • PRISM BioLab Blog – PPI Pursuit
    • Contact Us
    • Site Map
    © PRISM BioLab. All Rights Reserved
    Website by Axxiem
    Scroll to top
    en_USEnglish
    jaJapanese en_USEnglish
    en_US English
    en_US English
    ja Japanese